Key Points
- Director G. Leonard Baker Jr. bought 100,000 CORT shares on March 17 at an average price of $33.14 (about $3.31M), raising his stake ~9.6% to 1,146,631 shares—an insider vote of confidence.
- Recent quarter missed expectations: Corcept reported EPS of $0.20 vs. $0.33 expected and revenue $202.1M vs. $254.9M, while analyst actions have been mixed and the consensus rating is a Hold with a $77.17 target.
- Legal and regulatory risks are rising: investor suits citing an alleged FDA rejection and a federal court patent loss, plus multiple class‑action notices, could materially affect future revenue and investor sentiment.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were bought at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Corcept Therapeutics Stock Performance
Shares of Corcept Therapeutics stock opened at $34.08 on Friday. The business's 50 day moving average price is $37.52 and its 200 day moving average price is $62.18. The company has a market cap of $3.63 billion, a price-to-earnings ratio of 41.56 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $117.33.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company had revenue of $202.13 million during the quarter, compared to analysts' expectations of $254.94 million. During the same quarter in the previous year, the company earned $0.26 earnings per share. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. On average, research analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.
Analyst Ratings Changes
CORT has been the subject of a number of recent analyst reports. HC Wainwright cut their price target on shares of Corcept Therapeutics from $105.00 to $67.00 and set a "buy" rating for the company in a report on Friday, February 20th. Zacks Research lowered shares of Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 13th. Wolfe Research lowered shares of Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $30.00 target price for the company. in a research note on Wednesday, December 31st. UBS Group assumed coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a "neutral" rating and a $95.00 price target on the stock. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $77.17.
Read Our Latest Report on Corcept Therapeutics
Key Headlines Impacting Corcept Therapeutics
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: Director G. Leonard Baker Jr. purchased 100,000 CORT shares (~$3.3M) on March 17, increasing his stake by ~9.6%, a signal of insider confidence that can support the stock. SEC Form 4
- Neutral Sentiment: Reported short‑interest data show effectively zero reported short interest as of March 19 (data appear anomalous), so there’s no clear short‑seller pressure signal from this release. (May reflect reporting irregularities rather than investor behavior.)
- Negative Sentiment: Hagens Berman and other firms highlight an investor suit tied to an alleged FDA rejection and a federal court patent loss — items that can materially damage future revenue expectations and investor confidence. Hagens Berman Alert
- Negative Sentiment: Multiple shareholder‑rights firms (Schall, DJS, Rosen, Pomerantz, Glancy, Levi & Korsinsky, Robbins, etc.) issued class‑action/lead‑plaintiff notices for investors who bought CORT between Oct 31, 2024 and Dec 30, 2025 — a concentrated PR wave that keeps legal risk and potential liability top of mind for the market. Representative notice: Schall Law Firm. Schall Law Firm Notice
- Negative Sentiment: Zacks Research cut its Q3 2026 EPS estimate for CORT (from $0.30 to $0.21) and carries a "Strong Sell" view — analyst downgrades and lower guidance expectations can weigh on sentiment and valuation multiples.
Institutional Trading of Corcept Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Torren Management LLC acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $25,000. Advisory Services Network LLC purchased a new position in Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC grew its stake in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock worth $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of Corcept Therapeutics during the fourth quarter worth $31,000. Finally, Hantz Financial Services Inc. increased its position in shares of Corcept Therapeutics by 113.7% during the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 524 shares during the period. 93.61% of the stock is currently owned by hedge funds and other institutional investors.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
